Is Retatrutide with cagrilintide legal in Australia?

Two unapproved investigational drugs premixed by research chemical vendors, commonly 12.5 mg retatrutide with 2.5 mg cagrilintide in one vial. Neither has finished development, no compounding pharmacy or clinic supplies the pair, and the combination has never been tested in any species. Each component separately has good phase 2 data, which is what makes this look safer than it is.

This is the most aggressive product in the metabolic section and it is worth being precise about why. Both ingredients are real investigational drugs with real trials.

Mechanism: Retatrutide agonises three receptors: GIP, GLP-1 and glucagon. The glucagon arm is what distinguishes it and is also the arm that raises energy expenditure and can affect heart rate and hepatic glucose output.

Regulatory history: Neither component is approved anywhere in the world. Both are investigational, and no regulator has evaluated the combination.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Retatrutide with cagrilintide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.